In this study, we focused on establishing a therapeutic schedule with the proper dose for the treatment of lymphoma using a TLR7 agonist synthesised in our lab combined with chemotherapeutic drugs in a murine T cell lymphoma model. This evidence concerns the gene TLR7 and T-cell non-Hodgkin lymphoma.